 ChemoCentryx Incs NASDAQ: CCXI partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare MHLW to market Tavneos avacopan. Avacopan is an orally administered selective complement 5a receptor inhibitor in Japan for microscopic polyangiitis and granulomatosis with polyangiitis, forms of ANCA-associated vasculitis, or ANCA vasculitis. 